Patents by Inventor Ryotaro Mitsumata
Ryotaro Mitsumata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240207395Abstract: An adjuvant activity enhancer for a CpG-ODN or squalene-comprising emulsion, containing as an active ingredient a peptide nucleic acid to which a cell-penetrating peptide is bound. A method for enhancing an adjuvant activity of a CpG-ODN or squalene-comprising emulsion, including combining a peptide nucleic acid to which a cell-penetrating peptide is bound with the CpG-ODN or squalene-comprising emulsion.Type: ApplicationFiled: April 7, 2022Publication date: June 27, 2024Applicant: DENKA COMPANY LIMITEDInventor: Ryotaro MITSUMATA
-
Patent number: 12016920Abstract: Provided are an adjuvant useful for preparing a vaccine having high efficacy and high safety, and a vaccine composition comprising the adjuvant. The adjuvant comprises a peptide nucleic acid to which a cell penetrating peptide is bound.Type: GrantFiled: June 5, 2020Date of Patent: June 25, 2024Assignee: DENKA COMPANY LIMITEDInventors: Ryotaro Mitsumata, Asumi Kanda
-
Publication number: 20240181039Abstract: An influenza vaccine composition to be intranasally administered, including an influenza antigen to which TGDK is linked via a chemical bond.Type: ApplicationFiled: March 29, 2022Publication date: June 6, 2024Applicants: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Ryotaro MITSUMATA, Shogo MISUMI, Nagisa NAKATA, Naoki KISHIMOTO
-
Publication number: 20240156943Abstract: An influenza vaccine that has high immunogenicity in children and elderly people and has a higher efficacy than conventional split vaccines. An influenza vaccine composition to be administered to children and/or elderly people, including, as a virus antigen, inactivated whole particles subjected to inactivation treatment with beta-propiolactone.Type: ApplicationFiled: March 29, 2022Publication date: May 16, 2024Applicant: DENKA COMPANY LIMITEDInventors: Ryotaro MITSUMATA, Tomohiro NARAHARA
-
Patent number: 11890338Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.Type: GrantFiled: September 26, 2019Date of Patent: February 6, 2024Assignees: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Ryotaro Mitsumata, Shogo Misumi, Naoki Kishimoto, Takuma Gotanda, Nagisa Nakata
-
Publication number: 20230330221Abstract: Provided are an adjuvant useful for preparing a vaccine having high efficacy and high safety, and a vaccine composition comprising the adjuvant. The adjuvant comprises a peptide nucleic acid to which a cell penetrating peptide is bound.Type: ApplicationFiled: June 5, 2020Publication date: October 19, 2023Applicant: DENKA COMPANY LIMITEDInventors: Ryotaro MITSUMATA, Asumi KANDA
-
Patent number: 11707521Abstract: A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.Type: GrantFiled: September 26, 2019Date of Patent: July 25, 2023Assignees: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Shogo Misumi, Naoki Kishimoto, Ryotaro Mitsumata, Nagisa Nakata, Takuma Gotanda
-
Publication number: 20230147269Abstract: An inactivated influenza vaccine may have high immunogenicity and may be produced by method including performing inactivation treatment using formaldehyde including treating a virus solution containing an influenza virus collected from a host with ?-propiolactone in advance. The inactivation treatment using formaldehyde may be performed by adding formalin to the virus solution at a final concentration of 0.005 to 0.015 vol %.Type: ApplicationFiled: February 25, 2021Publication date: May 11, 2023Applicant: DENKA COMPANY LIMITEDInventors: Ryotaro MITSUMATA, Keiko YOSHIDA
-
Publication number: 20220331419Abstract: Provided is a seasonal influenza vaccine having a higher efficacy than a split vaccine. A seasonal influenza vaccine which induces virus-specific antibodies in the nasal mucosa, comprises inactivated whole influenza virus particles as an active ingredient, and is to be administered intradermally at dose per administration of 15 ?g HA or more per strain as antigen.Type: ApplicationFiled: September 2, 2020Publication date: October 20, 2022Applicant: DENKA COMPANY LIMITEDInventors: Ryotaro MITSUMATA, Asumi KANDA, Nagisa NAKATA, Shigetaka MIMORI
-
Publication number: 20220288224Abstract: Provided is a pharmaceutical agent for enhancing absorption efficiency of a drug through the mucosal epithelial layer. A pharmaceutical agent for transmucosal administration comprises as an active ingredient a drug compound to which a podocalyxin targeting molecule is bound.Type: ApplicationFiled: August 4, 2020Publication date: September 15, 2022Applicants: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Shogo MISUMI, Naoki KISHIMOTO, Ryotaro MITSUMATA
-
Publication number: 20220031833Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.Type: ApplicationFiled: September 26, 2019Publication date: February 3, 2022Applicants: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Ryotaro MITSUMATA, Shogo MISUMI, Naoki KISHIMOTO, Takuma GOTANDA, Nagisa NAKATA
-
Publication number: 20220031838Abstract: A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.Type: ApplicationFiled: September 26, 2019Publication date: February 3, 2022Applicants: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Shogo MISUMI, Naoki KISHIMOTO, Ryotaro MITSUMATA, Nagisa NAKATA, Takuma GOTANDA
-
Patent number: 10365277Abstract: Disclosed is a novel method for measuring haemagglutinin of an influenza virus, which can construct an assay system in a shorter period of time than a sandwich immunoassay method using two kinds of anti-haemagglutinin antibodies. The method for measuring haemagglutinin of an influenza virus is achieved by a sandwich immunoassay method comprising sandwiching the haemagglutinin between a lectin which binds to the haemagglutinin but does not bind to an antibody, and an anti-haemagglutinin antibody which undergoes antigen-antibody reaction with the haemagglutinin.Type: GrantFiled: October 3, 2013Date of Patent: July 30, 2019Assignee: DENKA SEIKEN CO., LTD.Inventors: Ryotaro Mitsumata, Noriyuki Izutani
-
Publication number: 20150233922Abstract: Disclosed is a novel method for measuring haemagglutinin of an influenza virus, which can construct an assay system in a shorter period of time than a sandwich immunoassay method using two kinds of anti-haemagglutinin antibodies. The method for measuring haemagglutinin of an influenza virus is achieved by a sandwich immunoassay method comprising sandwiching the haemagglutinin between a lectin which binds to the haemagglutinin but does not bind to an antibody, and an anti-haemagglutinin antibody which undergoes antigen-antibody reaction with the haemagglutinin.Type: ApplicationFiled: October 3, 2013Publication date: August 20, 2015Applicant: DENKA SEIKEN CO., LTD.Inventors: Ryotaro Mitsumata, Noriyuki Izutani